Newsfeeds - Spark Newswire

1 minute read

Earnings

Earnings Preview: Blueprint Medicines

Today, 7:52 AM

Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Blueprint Medicines will report an earnings per share (EPS) of $-1.65.

BPMC

3 minute read

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More

By Shanthi Rexaline

Today, 7:52 AM

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate proceedings, and the week also witnessed presentations at conferences and a couple of initial public offerings.

ADPT

2 minute read

Blueprint Medicines’ AYVAKYT Receives Positive CHMP Opinion For Treatment Of Adults With Advanced Systemic Mastocytosis

By Bill Haddad

Today, 7:52 AM

Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending to expand the

BPMC

1 minute read

Analyst Ratings

Analyst Ratings For Blueprint Medicines

By Benzinga Insights

Today, 7:52 AM

Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter:

BPMC

1 minute read

Stifel Upgrades Blueprint Medicines to Buy, Lowers Price Target to $95

By Benzinga Newsdesk

Today, 7:52 AM

Stifel analyst Bradley Canino upgrades Blueprint Medicines (NASDAQ:BPMC) from Hold to Buy and lowers the price target from $120 to $95.

BPMC

25 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 7:52 AM

During Friday's session, 445 companies made new 52-week lows.

AAOI

4 minute read

50 Biggest Movers From Yesterday

By Lisa Levin

Today, 7:52 AM

Gainers

AACG

3 minute read

34 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 7:52 AM

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers.

AACG

1 minute read

Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition

By Vandana Singh

Today, 7:52 AM

Blueprint Medicines Corporation (NASDAQ: BPMC) has

BPMC

1 minute read

Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates

By Vandana Singh

Today, 7:52 AM

Zai Lab Limited (NASDAQ:ZLAB) and Blueprint Medicines Corporation (NASDAQ:BPMC) have announced an exclusive collaboration and license agreement in Greater China, including mainland China,…

BPMC